Epizyme (Epizyme) Dividend Payout Ratio : 0.00 (As of Jun. 2022)

View and export this data going back to 2013. Start your Free Trial

What is Epizyme Dividend Payout Ratio?

Epizyme's dividend payout ratio for the months ended in Jun. 2022 was 0.00.

The historical rank and industry rank for Epizyme's Dividend Payout Ratio or its related term are showing as below:

EPZM's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-06), the Dividend Yield % of Epizyme is 0.00%.

Epizyme's Dividends per Share for the months ended in Jun. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Epizyme Dividend Payout Ratio Historical Data

The historical data trend for Epizyme's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epizyme Dividend Payout Ratio Chart

Epizyme Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dividend Payout Ratio

Get a 7-Day Free Trial

Epizyme Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Epizyme's Dividend Payout Ratio

For the Biotechnology subindustry, Epizyme's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Epizyme's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Epizyme's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Epizyme's Dividend Payout Ratio falls into.

Epizyme Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Epizyme's Dividend Payout Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2021 )	/	EPS without NRI (A: Dec. 2021 )
	=	0	/	-2.45
	=	N/A

Epizyme's Dividend Payout Ratio for the quarter that ended in Jun. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2022 )	/	EPS without NRI (Q: Jun. 2022 )
	=	0	/	-0.21
	=	N/A

Epizyme (NAS:EPZM) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Epizyme Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Epizyme's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Epizyme (Epizyme) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Epizyme Inc (NAS:EPZM) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Technology Square, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.epizyme.com

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.

Executives

Jeffery Kutok	officer: Chief Scientific Officer	784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jerald Korn	officer: Chief Operating Officer	128 GORDON RD, NEWTON MA 02468
Joseph Beaulieu	officer: Corporate Controller	C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Shefali Agarwal	officer: Chief Medical Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Royalty Pharma Investments 2019 Icav	director, 10 percent owner	C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022
Pablo G. Legorreta	director	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
Carol Stuckley	director	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Roy A Beveridge,	director	500 W MAIN ST, LOUISVILLE KY 40202
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Robert B Bazemore	director, officer: President & CEO	33 HAYDEN AVE, LEXINGTON MA 02421
Matthew Ros	officer: Chief Operating Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Tombesi	officer: Chief Financial Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Victoria Vakiener	officer: Chief Commercial Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Rp Management, Llc	director	110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022